North Chicago, IL-based AbbVie Inc. (ABBV - Free Report) is best known for its autoimmune disease drug, Humira. Other key products include Imbruvica (cancer) and Viekira Pak (hepatitis C virus (HCV) treatment).

Humira, the company’s flagship product which is approved for a wide range of indications, is a major contributor to AbbVie’s top line. While Humira will remain the key growth driver at AbbVie, the coming quarters will see investor focus remaining primarily on Viekira’s performance as well as pipeline updates.

Meanwhile, the Pharmacyclics acquisition has diversified AbbVie’s product portfolio with the addition of Imbruvica.

AbbVie’s performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. The average earnings beat over the last four quarters is 1.92%.

AbbVie Inc. Price

AbbVie Inc. Price | AbbVie Inc. Quote

Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: AbbVie's fourth-quarter earnings came in at $1.20 per share, in-line with the Zacks Consensus Estimate.

Revenues: AbbVie posted revenues of $6.80 billion, missing the Zacks Consensus Estimate of $6.92 billion.

Key Stats: Humira sales came in at $4.3 billion. Fourth-quarter Imbruvica sales were $511 million. Viekira sales were $311 million in the fourth quarter.

2017 Outlook: AbbVie provided its outlook for 2017. The company expects adjusted EPS in the range of $5.44–$5.54. The Zacks Consensus Estimate is currently pegged at $5.48 per share.